Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1B | P28222 | 6/20 | 0.58 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 8/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.50 |
| ▸ | HTR1A | P08908 | 4/20 | 0.50 |
| ▸ | HTR1D | P28221 | 4/20 | 0.50 |
| ▸ | NPC1 | O15118 | 2/20 | 0.50 |
| ▸ | RAB9A | P51151 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | HTR2C | P28335 | 2/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | MTOR | P42345 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | RAD52 | P43351 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6816404 | 1.00 | HTR1B (0.58) | HTR1BKCNH2MAPTALDH1A1HTR1A | |
| SCHEMBL6816431 | 1.00 | HTR1B (0.58) | HTR1BKCNH2MAPTALDH1A1HTR1A | |
| SCHEMBL6823346 | 0.90 | KMT2A (0.53) | HTR1BKCNH2ALDH1A1HTR1AHTR1D | |
| SCHEMBL6820517 | 0.90 | KMT2A (0.53) | HTR1BKCNH2ALDH1A1HTR1AHTR1D | |
| SCHEMBL6820391 | 0.86 | MAPT (0.56) | HTR1BKCNH2MAPTALDH1A1NPC1 | |
| SCHEMBL7062951 | 0.86 | HTR1B (0.52) | HTR1BKCNH2MAPTALDH1A1HTR1A | |
| SCHEMBL7063234 | 0.86 | HTR1B (0.52) | HTR1BKCNH2MAPTALDH1A1HTR1A | |
| SCHEMBL7063741 | 0.86 | HTR1B (0.52) | HTR1BKCNH2MAPTALDH1A1HTR1A | |
| SCHEMBL6820063 | 0.85 | HTR1B (0.53) | HTR1BKCNH2MAPTALDH1A1HTR1A | |
| SCHEMBL6816583 | 0.83 | MAPT (0.52) | HTR1BKCNH2MAPTALDH1A1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1014986-B1 | A COMBINATION OF A MONOAMINE OXIDASE INHIBITOR AND A h5-HT 1 BETA ANTAGONIST OR PARTIAL AGONIST | ASTRAZENECA AB (SE) | 2004-07-14 | — | — | EP | claimed |
| EP-1021183-B1 | A COMBINATION OF A SELECTIVE 5-HT1A ANTAGONIST AND A SELECTIVE h5-HT1B ANTAGONIST OR PARTIAL AGONIST | ASTRAZENECA AB (SE) | 2004-03-17 | — | — | EP | claimed |
| EP-1014985-B1 | A COMBINATION OF A 5-HT REUPTAKE INHIBITOR AND A H5-HT 1B ANTAGONIST OR PARTIAL AGONIST | ASTRAZENECA AB (SE) | 2003-05-21 | — | — | EP | claimed |
| EP-1000048-B1 | SUBSTITUTED 1,2,3,4-TETRAHYDRONAPHTHALENE DERIVATIVES | ASTRAZENECA AB (SE) | 2002-11-27 | — | — | EP | claimed |
| US-20010051626-A1 | 8-(Piperidin-4-yl- or piperazin-1-yl)-2-substituted-tetralin derivatives; selective effect at a subgroup of 5-hydroxy-tryptamine receptors, h5-HT1B receptors (previously 5-HT1D beta); antagonists; mood disorders, antianxiolytic | ASTRAZENECA AB (SE) | 2001-12-13 | — | — | US | claimed |
| US-6313118-B1 | HYDROXYTRYPTAMINE RECEPTOR ANTAGONISTS | ASTRA AKTIEBOLAG (SE) | 2001-11-06 | — | — | US | claimed |
| US-6159970-A | Combination of a monoamine oxidase inhibitor and a h5-HT1B antagonist or partial agonist | ASTRAZENECA AB (SE) | 2000-12-12 | — | — | US | claimed |
| US-6159972-A | Combination of a selective 5-HT1A antagonist and a selective ub. h5-HT.s1B antagonist or partial agonist | ASTRAZENECA AB (SE) | 2000-12-12 | — | — | US | claimed |
| EP-1014986-B1 | A COMBINATION OF A MONOAMINE OXIDASE INHIBITOR AND A h5-HT 1 BETA ANTAGONIST OR PARTIAL AGONIST | ASTRAZENECA AB (SE) | 2004-07-14 | — | — | EP | disclosed |
| EP-1021183-B1 | A COMBINATION OF A SELECTIVE 5-HT1A ANTAGONIST AND A SELECTIVE h5-HT1B ANTAGONIST OR PARTIAL AGONIST | ASTRAZENECA AB (SE) | 2004-03-17 | — | — | EP | disclosed |
| EP-1014985-B1 | A COMBINATION OF A 5-HT REUPTAKE INHIBITOR AND A H5-HT 1B ANTAGONIST OR PARTIAL AGONIST | ASTRAZENECA AB (SE) | 2003-05-21 | — | — | EP | disclosed |
| US-6534652-B2 | 8-(Piperidin-4-yl- or piperazin-1-yl)-2-substituted-tetralin derivatives; selective effect at a subgroup of 5-hydroxytryptamine receptors, h5-HT1B receptors (previously 5-HT1D beta); antagonists; mood disorders, antianxiolytic | ASTRAZENECA AB (SE) | 2003-03-18 | — | — | US | disclosed |
| EP-1000048-B1 | SUBSTITUTED 1,2,3,4-TETRAHYDRONAPHTHALENE DERIVATIVES | ASTRAZENECA AB (SE) | 2002-11-27 | — | — | EP | disclosed |
| US-6410532-B2 | 8-(PIPERIDIN-4-YL- OR PIPERAZIN-1-YL)-2-SUBSTITUTED-TETRALIN DERIVATIVES; SELECTIVE EFFECT AT A SUBGROUP OF 5-HYDROXY-TRYPTAMINE RECEPTORS, H5-HT1B RECEPTORS (PREVIOUSLY 5-HT1D BETA); ANTAGONISTS; MOOD DISORDERS, ANTIANXIOLYTIC | ASTRAZENECA AB (SE) | 2002-06-25 | — | — | US | disclosed |
| EP-1014986-A1 | A COMBINATION OF A MONOAMINE OXIDASE INHIBITOR AND A h5-HT 1 BETA ANTAGONIST OR PARTIAL AGONIST | AstraZeneca AB (SE) | 2000-07-05 | — | — | EP | disclosed |
| EP-1000048-A1 | SUBSTITUTED 1,2,3,4-TETRAHYDRONAPHTHALENE DERIVATIVES | Astra Aktiebolag (SE) | 2000-05-17 | — | — | EP | disclosed |
| WO-1999013878-A1 | A COMBINATION OF A MONOAMINE OXIDASE INHIBITOR AND A h5-HT1B ANTAGONIST OR PARTIAL AGONIST | ASTRAZENECA AB (SE) | 1999-03-25 | — | — | WO | disclosed |
| WO-1999013876-A1 | A COMBINATION OF A SELECTIVE 5-HT1A ANTAGONIST AND A SELECTIVE h5-HT1B ANTAGONIST OR PARTIAL AGONIST | ASTRAZENECA AB (SE) | 1999-03-25 | — | — | WO | disclosed |
| WO-1999013877-A1 | A COMBINATION OF A 5-HT REUPTAKE INHIBITOR AND A h5-HT1B ANTAGONIST OR PARTIAL AGONIST | ASTRAZENECA AB (SE) | 1999-03-25 | — | — | WO | disclosed |
| WO-1999005134-A1 | SUBSTITUTED 1,2,3,4-TETRAHYDRONAPHTHALENE DERIVATIVES | ASTRA AKTIEBOLAG (SE) | 1999-02-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010051626-A1 | 8-(Piperidin-4-yl- or piperazin-1-yl)-2-substituted-tetralin derivatives; selective effect at a subgroup of 5-hydroxy-tryptamine receptors, h5-HT1B receptors (previously 5-HT1D beta); antagonists; mood disorders, antianxiolytic | HTR1D, HTR1F, HTR2C | HTR1B 6/4885KCNH2 390/4885MAPT 3250/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.